Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Edwards Lifesciences is a medical devices business based in the US. Edwards Lifesciences stocks (EW.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $81.57 – an increase of 2.44% over the previous week. Edwards Lifesciences employs 17,300 staff and has a trailing 12-month revenue of around $5.4 billion.
Finder Award
Interactive Brokers
National Bank Direct Brokerage
| Latest market close | $82.73 |
|---|---|
| 52-week range | $67.13 - $131.10 |
| 50-day moving average | $78.87 |
| 200-day moving average | $84.54 |
| Wall St. target price | $87.45 |
| PE ratio | 33.4303 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.44 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $82.73 from 2023-03-31
| 1 week (2023-03-24) | 2.44% |
|---|---|
| 1 month (2023-03-02) | 3.12% |
| 3 months (2022-12-30) | 10.88% |
| 6 months (2022-09-30) | 0.12% |
| 1 year (2022-03-30) | -29.34% |
|---|---|
| 2 years (2021-04-01) | -1.32% |
| 3 years (2020-04-02) | 184.86 |
| 5 years (2018-04-02) | 135.45 |
Valuing Edwards Lifesciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $5.4 billion |
|---|---|
| Operating margin TTM | 33.29% |
| Gross profit TTM | $4.3 billion |
| Return on assets TTM | 13.34% |
| Return on equity TTM | 26.14% |
| Profit margin | 28.28% |
| Book value | $9.55 |
| Market capitalisation | $50.1 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.68
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences's overall score of 21.68 (as at 01/01/2019) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.78/100
Edwards Lifesciences's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.43/100
Edwards Lifesciences's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.96/100
Edwards Lifesciences's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences has, for the most part, managed to keep its nose clean.
We're not expecting Edwards Lifesciences to pay a dividend over the next 12 months.
Edwards Lifesciences's shares were split on a 3:1 basis on 1 June 2020. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences shares which in turn could have impacted Edwards Lifesciences's share price.
Over the last 12 months, Edwards Lifesciences's shares have ranged in value from as little as $67.13 up to $131.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences's is 1.0056. This would suggest that Edwards Lifesciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Earn cash, rewards points, bonus interest rates and more with these new bank account offers and promotions.
Find out where you can apply for some of the best bad credit loans in Saskatchewan, and learn how to increase your chances of getting approved.
Compare alternatives to AutoTrader in Canada.
This spending app uses games and quizzes to teach kids about finances. GoHenry isn’t in Canada, but there are alternatives.
Find out how major crypto exchanges and brokers fared in 2023’s Crypto Trading Platform Awards.
Foreigners and non-residents entering Canada can open a bank account with the right identification.
Your guide to the exchange rates, fees and processing times of Lemonade Finance international money transfers.
Avoid or lower your international transaction fees when shopping online or travelling overseas.
70% of Canadians are willing to make less on their investments to invest in a socially responsible way.
These providers offer similar loans to Advance America for quick cash.
